ArticleCurrent drug delivery2026
Cancer Cell-Coated PLGA Nanoparticles Loaded with Sorafenib and Spions for Hepatocellular Carcinoma Theranostics.
Article in Current drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sorafenib nanomedicine in HCC: nano-bio interactions and combination therapies.Journal of nanobiotechnology · 2026Review
- Nanomaterial-based strategies to overcome sorafenib resistance in hepatocellular carcinoma: from mechanistic insights to translational applications.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHepatocellular carcinoma (HCC) is the sixth most common malignant cancer worldwide, but the chemotherapy drugs used in the treatment of HCC patients have limited efficacy and cause severe side effects. To improve HCC treatment outcomes, a cancer cell membrane (CCM)-coated biomimetic nanodelivery system was designed to achieve enhanced anti-HCC effects.
methodsPoly (lactic-co-glycolic acid) (PLGA) was used to carry both sorafenib, which is used to treat advanced HCC, and superparamagnetic iron oxide nanoparticles (SPIONs). The prepared nanoparticles (NPs) were coated with Huh-7 cell membranes to obtain biomimetic nanoparticles (SFINPs@CCM). The physicochemical properties of SFINPS@CCM were then characterized, and the drug loading efficiency, release rate, transverse relaxation rate for MRI, fluorescence targeting ability, and anti-HCC ability were evaluated.
resultsThe SFINPS@CCM were successfully prepared. The loading efficiency of sorafenib in the SFINPs was 88.24%. The cumulative amount of sorafenib released from the SFINPs@CCM at 72 h was 72.96%. In vitro magnetic resonance imaging (MRI) showed the transverse relaxation rate was 25.448 mM DISCUSSION: The study indicates that the SFINPs@CCM system achieves efficient drug delivery and enhances anti-HCC efficacy. While the results are encouraging, further research is needed to confirm broader applicability.
conclusionThe biomimetic nanodelivery system exhibits good targeting and excellent therapeutic effects, laying a technical foundation for preclinical studies.
Indexed as
Identifiers
40735995What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.